LATS2 and hepatocellular carcinoma: In this scenario, JCAD binds to the domain of LATS2 kinase and inhibits the ability of LATS2 to phosphorylate YAP, which in turn activating YAP to promote hepatoma cell proliferation (Fig. 3b) [59].